8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

——————

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):  July 8, 2015

DYNATRONICS CORPORATION

(Exact name of registrant as specified in its charter)

	Utah	0-12697	87-0398434
(State or Other Jurisdiction of Incorporation)		Commission File Number	(IRS Employer Identification Number)

7030 Park Centre Dr., Salt Lake City, Utah                            84121

(Address of principal executive offices)                            (Zip Code)

Registrant's telephone number, including area code: (801) 568-7000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02                      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

In connection with the closing of the private placement of preferred stock reported previously by Dynatronics Corporation (“Registrant”) in a Current Report on Form 8-K filed on July 1, 2015, on July 8, 2015 Registrant appointed Erin S. Enright, 53, and Brian Larkin, 46, as directors.  Ms. Enright and Mr. Larkin serve as Preferred Directors nominated by the holders of the Registrant’s Series A 8% Convertible Preferred Stock (the “Preferred Stock”).  The holders of the Preferred Stock have the right to appoint up to three members of the Registrant’s board of directors. An additional appointment is anticipated to be made in the future.

Ms. Enright is a Managing Member of Prettybrook Partners, LLC, a private investment firm, and a general partner and member of the Board of Tigerlabs, a Princeton-based business accelerator. She was the President of Lee Medical, a medical device manufacturer based in Plainsboro, New Jersey, from 2004-2013. She served on the Board of Directors and the Audit Committee of Biolase, Inc. (NASDAQ: BIOL) during 2013, and from 2010 to 2013, served on the Board of Directors of Ceelite Technologies, LLC.  Ms. Enright served as Chief Financial Officer of InfuSystem, Inc. from 2005 to 2007. From 1993 to 2003, Ms. Enright was with Citigroup, most recently as a Managing Director in its Equity Capital Markets group. While at Citigroup, Ms. Enright was Chairperson of the firm’s Institutional Investors’ Committee, responsible for screening and approving the firm’s participation in equity underwritings, and a member of the Citigroup Global Equity Commitment Committee, responsible for reviewing and approving the firm’s underwritings. From 1989 until 1993, Ms. Enright was an attorney with Wachtell, Lipton, Rosen & Katz in the firm’s New York office. Ms. Enright received her A.B. from the Woodrow Wilson School of Public and International Affairs at Princeton University and a J.D. from the University of Chicago Law School.

Since May 2015, Mr. Larkin has been the Senior Vice President and General Manager for the Regenerative Medicine business at Acelity L. P., Inc.  Prior to joining Acelity, Mr. Larkin was Corporate Vice President of Integra Lifesciences Holdings Corporation, where he served as President of the Global Spine and Orthobiologics businesses, and Head of Strategic Development of Integra. His responsibilities included executive oversight and leadership of Integra’s worldwide Spine and Orthobiologics businesses, in addition to executive oversight of several of Integra’s corporate functions, including corporate marketing and strategic planning. Mr. Larkin joined Integra in January 2000 as a Regional Sales Manager. He was promoted to National Sales Manager in 2003, Vice President, North American Sales in 2005, and President of Integra’s Neurosurgery business in 2007. In 2010 he was appointed President, Global Spine & Orthobiologics, and Head of Strategic Development. Mr. Larkin has over 24 years of sales, marketing, and executive management experience in the medical technology industry. Prior to joining Integra, he was the National Sales Manager for Connell Neurosurgical. Mr. Larkin received a B.S. degree in Chemistry from the University of Richmond, and completed the Advanced Management Program at Harvard Business School.

Item 9.01.                      Financial Statements and Exhibits.

(d)           Exhibits.

Registrant issued a press release announcing the appointment of Ms. Enright and Mr. Larkin to the Registrant’s board of directors on July 8, 2015.  A copy of the press release is furnished with this Current Report as Exhibit 99.1.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 DYNATRONICS CORPORATION

 By: /s/ Kelvyn H. Cullimore

        Kelvyn H. Cullimore, Jr.

        Chief Executive Officer

Date: July 8, 2015

3

EXHIBITS

Exhibit 99.1                                Press Release, July 8, 2015

EX-99.1

Exhibit 99.1

NEWS RELEASE

Contact: Bob Cardon, Dynatronics Corporation                                                                                                                                

           800-874-6251 or 801-568-7000

DYNATRONICS ANNOUNCES APPOINTMENT OF

ERIN ENRIGHT AND BRIAN LARKIN TO ITS BOARD OF DIRECTORS

COTTONWOOD HEIGHTS, UT (July 8, 2015) - Dynatronics Corporation (NASDAQ: DYNT), a manufacturer and marketer of rehabilitation and physical therapy products, announced today the appointments of Erin Enright and Brian Larkin to its board of directors.  This expansion of the board of directors was contemplated as part of the recent investment in Dynatronics led by Prettybrook Partners that closed on June 30, 2015.

“We welcome Erin and Brian as new members of our board and appreciate their willingness to serve,” said Kelvyn Cullimore Jr., Dynatronics’ chairman and CEO. “Their depth of experience in the healthcare industry and many years of proven leadership bring important expertise to help us transform Dynatronics and take full advantage of the partnership with Prettybrook and its affiliates.”

Erin Enright has held numerous positions in the healthcare industry over her career, including CEO of Lee Medical, a privately held medical device company, CFO of InfuSystem Holdings Inc. (NYSE Market: INFU), managing partner of Prettybrook Partners, LLC, and a former board member of Biolase, Inc. (NASDAQ: BIOL). Previously, she was a managing director in the equity capital markets group at Citibank, where she worked for over a decade. She received her A.B. degree from Princeton University and J.D. degree from the University of Chicago.

Since May 2015, Mr. Larkin has been the Senior Vice President and General Manager for the Regenerative Medicine business at Acelity L.P., Inc.  Prior to joining Acelity, Mr. Larkin was Corporate Vice President of Integra Lifesciences Holdings Corporation and President — Global Spine and Orthobiologics, and Head of Strategic Development of Integra. Mr. Larkin has over 24 years of sales, marketing, and executive management experience in the medical technology industry. Prior to joining Integra, he was the National Sales Manager for Connell Neurosurgical. Mr. Larkin received a B.S. degree in Chemistry from the University of Richmond, and completed the Advanced Management Program at Harvard Business School.

“We look forward to working with Erin and Brian and express our gratitude for the contributions they will make to benefit the shareholders of Dynatronics,” added Cullimore.

About Dynatronics

Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets. More information regarding Dynatronics is available at www.dynatronics.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements. Those statements include references to the company’s expectations and similar statements. Actual results may vary from the views expressed in the forward-looking statements contained in this release. The development and sale of the company’s products are subject to a number of risks and uncertainties, including, but not limited to, changes in the regulatory environment, competitive factors, inventory risks due to shifts in market demand, market demand for the company’s products, availability of financing at cost-effective rates, and the risk factors listed from time to time in the company’s SEC reports.